Paul L. M. van Giersbergen

Author

Also Known As

P L M van Giersbergen, P L.M. van Giersbergen, P. L. M. VAN GIERSBERGEN, P. L. M. Van Giersbergen, P. L. M. van Giersbergen, P.L.M. Van Giersbergen, P.L.M. van Giersbergen, PAUL L. M. VAN GIERSBERGEN, Paul L M van Giersbergen, Paul L M. van Giersbergen

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Actelion (Switzerland)University of Cincinnati

About

Paul L. M. van Giersbergen is an author at Actelion (Switzerland) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	24	732
2	Biochemistry	6	6	296
3	Health Sciences	5	5	97
4	Public Health	1	1	22
5	Anesthesia	1	1	81

Paul L. M. van Giersbergen

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
First‐in‐man safety and pharmacokinetics of synthetic ozonide <scp>OZ439</scp> demonstrates an improved exposure profile relative to other peroxide antimalarials Joerg J. Moehrle, Stephan Duparc, Christoph Siethoff, British Journal of Clinical Pharmacology	2012	115
Macitentan: entry-into-humans study with a new endothelin receptor antagonist Patricia N. Sidharta, Paul L. M. van Giersbergen, Atef Halabi, European Journal of Clinical Pharmacology	2011	107
A toxin from the green mamba <i>Dendroaspis angusticeps</i>: Amino acid sequence and selectivity for muscarinic m4 receptors Mikael Jolkkonen, Paul L. M. van Giersbergen, Ulf Hellman, FEBS Letters Muscarinic M4 ReceptorsAmino AcidsBiochemistryMuscarinic Toxin 3Medicine	1994	93
Single‐ and multiple‐dose pharmacokinetics of bosentan and its interaction with ketoconazole Paul L. M. van Giersbergen, Atef Halabi, Jasper Dingemanse British Journal of Clinical Pharmacology	2002	86
Pharmacological properties of dolasetron, a potent and selective antagonist at 5‐HT<sub>3</sub> receptors Robert C. Miller, Martin Galvan, Maurice W. Gittos, Drug Development Research Sympathetic Nerve TerminalsPharmacotherapyExperimental PharmacologySelective AntagonistPre-clinical Pharmacology	1993	81
Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple‐dose study in healthy subjects Patricia N. Sidharta, Paul L. M. van Giersbergen, Jasper Dingemanse The Journal of Clinical Pharmacology	2013	77
Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects Paul L. M. van Giersbergen, Alexander Treiber, R Schneiter, Clinical Pharmacology & Therapeutics	2007	76
Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol Paul L. M. van Giersbergen, Atef Halabi, Jasper Dingemanse International Journal of Clinical Pharmacology and Therapeutics	2006	65
Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists Mary H. Richards, Paul L. M. van Giersbergen British Journal of Pharmacology	1995	64
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide Paul L. M. van Giersbergen, Alexander Treiber, Martine Clozel, Clinical Pharmacology & Therapeutics	2002	64

Page 1